Galderma has reported positive data from a Phase III clinical trial of RelabotulinumtoxinA for treating frown lines and ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

During IDWeek 2024 in the US, novel antimicrobials in the development pipeline that are poised to make a difference were ...

Madrigal Pharmaceuticals has finished enrolling patients in a trial of Rezdiffra, a drug candidate for compensated NASH ...

Zymeworks has dosed the first subject in a Phase I trial of ZW171 to treat ovarian cancer, non-small cell lung cancer and ...

At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II dose-ranging trial for mRNA-1403, a vaccine ...

Roche has released positive topline one-year findings from a Phase IV trial of Vabysmo (faricimab) to treat diabetic macular ...

Sepsis is a life-threatening complication arising from an infection, which occurs when the body’s response to the infection ...

Find Therapeutics has dosed the first subject in a Phase I trial of FTX-101 as a potential treatment for chronic optic ...

Nurix Therapeutics has reported positive clinical data from its ongoing Phase Ia/Ib trial of NX-5948 for Waldenstrom's ...

A partial hold was placed on the trial after results showed variance between squamous and non-squamous NSCLC patient ...

The RightAI platform aims to assist clinicians in selecting the right patients for clinical trials and make precise treatment ...